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Activation of the transcription factor NF-kB has been
linked to apoptosis, with the factor playing either an
anti-apoptotic or a pro-apoptotic role, depending on the
type of cell in which it is expressed. 
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The transcription factor NF-kB has for some years been rec-
ognized to be a central mediator of the gene expression in-
duced in cells by pathogens or inflammatory cytokines, and
is known to play an important role in development of the
immune system [1]. To the list of NF-kB’s biological activi-
ties can now be added a role in countering the induction of
apoptosis (or programmed cell death) by the cytokine tumor
necrosis factor-a (TNF-a), ionizing radiation or the cancer
chemotherapeutic agent daunorubicin [2–6].
The form of active cell death known as apoptosis is an
important process in embryogenesis and lymphoid cell
development that results in selective elimination of cells
from the body. Once the decision to undergo cellular
suicide has been made, a proteolytic cascade is triggered
in the cell, which ultimately results in activation of nucle-
ases that degrade chromosomal DNA [7]. Cells exposed to
DNA-damaging agents or TNF-a, treatments that are
known to induce NF-kB activation, in combination with a
protein or RNA synthesis inhibitor also undergo apoptosis.
Several recent papers [2–6] have now shown that activa-
tion of NF-kB by these agents is part of a regulatory loop
that operates to prevent cell death, most likely by induc-
ing the expression of anti-apoptotic genes.
An inkling of a connection between NF-kB and cell death
came from studies on ‘knockout’ mice that lack the 65 kDa
RelA subunit (also known as p65) of NF-kB as a result of
targeted mutation of the relA gene. These mice die before
birth and show massive degeneration of liver cells caused
by apoptosis, suggesting that, in mice, NF-kB has a protec-
tive role, at least during early liver development [8]. Beg
and Baltimore [2] have now demonstrated that fibroblasts
and macrophages from the RelA-deficient mice are sensi-
tized to TNF-a-induced cytotoxicity and die within eight
hours of exposure to the cytokine, whereas wild-type cells
survive the treatment. The susceptibility of the RelA-defi-
cient cells to TNF-a-induced toxicity is reversed following
transfection of the cells with the wild-type relA gene,
arguing against the view that the cells suffer a gross devel-
opmental defect that predisposes them to apoptosis. 
It had previously been shown that cells from the relA
knockout mice do not respond to TNF-a by activation of
NF-kB or the induction of normally TNF-a-responsive
genes with NF-kB-binding (kB) promoter sites [2]. The
simplest conclusion from these observations is that one or
more of the NF-kB-dependent genes that are induced by
TNF-a protect cells from apoptosis. Such a scenario also
helps explain why, in most cell types, TNF-a is not
cytotoxic unless the cells are simultaneously exposed to an
inhibitor of RNA or protein synthesis, which may block
expression of NF-kB-dependent genes that have a
protective function (see Fig. 1a).
A requirement of NF-kB for preventing apoptosis has also
been shown by functionally inactivating the NF-kB
transcription factor in RelA-expressing cells [3–7]. Proto-
typical NF-kB, a heterodimer of RelA and 50 kDa subunit
(p50), is usually retained in the cytoplasm of unstimulated
cells in an inactive form by members of the inhibitory
protein (IkB) family. Following cell stimulation, IkB-a is
rapidly phosphorylated at two serine residues near its
amino terminus, which targets this subunit for proteolytic
degradation. The released NF-kB can then translocate to
the nucleus, where it activates the transcription of target
genes. Mutation of IkB-a so that it can no longer be
inducibly phosphorylated creates a dominant-negative
form that, when expressed in cells, potently suppresses
activation of the entire NF-kB family.
Several groups have demonstrated that cells expressing
such a dominant-negative mutant form of IkB-a are killed
by TNF-a, even in the absence of a protein synthesis
inhibitor [3–6]. Conversely, pretreatment of cells with
interleukin 1b (IL-1b), a cytokine that activates NF-kB
but is not pro-apoptotic, protects them from apoptosis
induced by the later addition of TNF-a plus a protein
synthesis inhibitor. In cells already expressing the domi-
nant-negative IkB-a, IL-1b does not have a protective
effect, suggesting that the effect of IL-1b also relies on
the induction of NF-kB-controlled anti-apoptotic genes.
A role for NF-kB in preventing apoptosis is also evident in
B-lymphocyte cell lines. Such cell lines express constitu-
tively active NF-kB, and inactivation of the factor by
various means induces apoptosis [6]. When murine B
lymphoma cells are treated with protease inhibitors or
antioxidant compounds known to inhibit NF-kB activation,
or microinjected with IkB-a, they die showing features
characteristic of apoptosis. Thus, in B cells, constitutive
NF-kB has an role in ensuring cell survival, and thereby
cell proliferation. As B-cell proliferation is exquisitely stim-
ulated by pro-inflammatory conditions, constitutive NF-kB
activation in this cell type may have evolved to ensure a
more permanent protection of cells from the enhanced
levels of pro-apoptotic cytokines present in inflamed areas
of the organism.
Wang et al. [3] have demonstrated that cells with inactivated
NF-kB are also more prone to commit suicide in response
to pro-apoptotic stimuli other than the inflammatory
cytokine TNF-a. DNA-damaging agents, such as ionizing
radiation and daunorubicin, which can also activate NF-kB,
are more toxic to cells when NF-kB activation is blocked by
expression of a dominant-negative IkB-a mutant. An
important therapeutic implication of these observations is
that it may be possible to enhance the efficacy of anti-
cancer drugs by inhibiting NF-kB activation. Several anti-
cancer compounds are cytotoxic and kill tumor cells by
inducing apoptosis. By combining cancer chemotherapeu-
tics with a compound that blocks NF-kB activation their
anti-tumor activity may be enhanced (see Fig. 1b). 
The putative anti-apoptotic genes that are activated by
NF-kB in response to endogenous TNF-a and exogenous
genotoxic and stress-inducing conditions remain to be
identified. Two likely candidates are the genes for man-
ganese superoxide dismutase and the zinc finger protein
A20. Expression of both genes is induced by TNF-a and
the two protein products provide partial protection against
apoptosis when expressed constitutively [9,10]. In the
case of A20, NF-kB was identified as a key transcriptional
regulator of its expression. However, a role of NF-kB in
regulation of manganese superoxide dismutase gene
expression has not been established yet. 
Multicellular organisms appear to have evolved an intricate
strategy of linking NF-kB activation with protection from
apoptosis. A major purpose of this connection may be to
avoid unnecessary cell suicide in response to certain pro-
apoptotic signals, such as TNF-a. Only when TNF-a hits a
cell that is incapable of mounting a NF-kB-dependent
genetic response — because the cell is damaged or its
protein or RNA synthesis is inhibited by small molecules or
a viral mechanism — would the cell be killed by an other-
wise tolerable stimulus. This way, the organism can screen
itself for the presence of damaged or infected cells and
eliminate them while the transcriptionally and translation-
ally functional cells would stay alive. NF-kB is thus a key
regulator that connects the execution of the apoptotic
program with an interpretation of the functional state of the
cell’s protein expression machinery. 
NF-kB plays a pivotal role in defending the organism
against viruses by inducing the expression of various
antiviral proteins in response to viral proteins or viral
RNA intermediates. One way for viruses to subvert this
control would be to block NF-kB activation by some
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Roles of NF-kB in the regulation of cell death. The cell type and stimulus
determines whether NF-kB activation protects cells from apoptosis or
promotes cell death. (a) Binding of TNF-a to TNF receptor subtype 1
(TNF-R1) can trigger both NF-kB activation and apoptosis. Activated
NF-kB induces the expression of gene products that block the apoptotic
pathway. Preventing the induction of the anti-apoptotic genes by
interfering with protein or RNA synthesis, or by inactivating NF-kB
functionally, genetically or pharmacologically, promotes apoptosis. IL-1
can only induce NF-kB, and so pretreating cells with IL-1 makes them
more resistant to apoptotic signals. (b) Several anti-cancer drugs
activate NF-kB in addition to inducing cell death. NF-kB activation may
counteract the therapeutic effects of these compounds, and combining
anti-cancer therapies with NF-kB blocking agents might result in more
effective anti-cancer treatments. (c) In neuronal cells, glutamate-induced
toxicity is accompanied by NF-kB activation. However, NF-kB may
induce the expression of pro-apoptotic genes in these cells to facilitate
cell death. Binding of NGF to its low-affinity receptor p75NTR on
Schwann cells results in NF-kB activation. The relationship, if any,
between NF-kB activation and cell death triggered by p75NTR activation
in these cells is not established.
R96 Current Biology, Vol 7 No 2
NF-kB-inhibitory mechanism acquired during their evo-
lution, as is the case with the African Swine Fever Virus,
the genome of which actually encodes an IkB-like
inhibitor. In such a situation, however, the virus-infected
cell with an inactivated NF-kB would become more sensi-
tive to stimuli that induce apoptotic death, such as TNF-
a, particularly once the virus attempts to subvert and
control the cell’s protein expression machinery.
A general role for NF-kB as a transcription factor that
prevents cell death is, however, far from established. A
recent study with neurons suggests that NF-kB can have
the opposite role [11]. Glutamate-induced toxicity in neu-
ronal cells was found to be accompanied by the induction
of NF-kB. In this case, NF-kB activation appears to cause
cell death, as blocking its activation with aspirin or salicy-
late protected the cells from the neurotoxic effects of gluta-
mate [11]. If this study can be extended to other
NF-kB-activating neurotoxins, such as b amyloid peptide,
then it seems that, in neurons, unlike several other cell
types, NF-kB maybe involved in triggering cell death (Fig.
1c). In Schwann cells, nerve growth factor (NGF) has been
shown to activate NF-kB through the neurotrophin recep-
tor p75 [12]. It would be interesting to determine if NF-kB
performs a pro-apoptotic or anti-apoptotic role in this glial
cell type, as the p75 receptor is believed to mediate both
cell survival and cell death, depending on the developmen-
tal state of neurons and the amount of receptor expressed.
Two other reports have also implicated NF-kB in promot-
ing apoptosis [13,14]. In one study [13], apoptotic death
induced in a human embryonic kidney cell line (293 cells)
by serum withdrawal was shown to be accompanied by
NF-kB activation. Interestingly, transient or stable over-
expression of bcl-2, the product of which is known to inter-
fere with apoptosis, reduced kB-dependent reporter gene
expression and prevented cell death. Conversely, overex-
pression of a dominant-negative form of RelA, capable of
suppressing kB-dependent gene expression, resulted in
partial inhibition of apoptosis. In the other study [14],
Sindbis-Virus-induced apoptosis in a carcinoma cell line
was similarly shown to require NF-kB activation. Thus,
there are clearly situations in which NF-kB activation
appears to be required for apoptosis to occur. In this
respect, it is interesting to note that the list of target genes
for NF-kB include both anti-apoptotic (see above) and
pro-apoptotic genes, such as c-myc and p53 [1]. 
The role of NF-kB as a promoter or attenuator of cell death
may ultimately depend on both the cell type and the nature
of the apoptosis-inducing stimulus. In different cell types,
NF-kB could perform these opposing functions by activat-
ing distinct patterns of genes in conjunction with cell-type-
specific transcription factors. Apoptosis-inducing stimuli
may differ with respect to the kind of pathways they can
activate in addition to the ones controlling apoptosis and
NF-kB. Additional activated transcription factors, such as
AP-1 or Ets factors, may further influence the spectrum of
induced genes to determine whether NF-kB can oppose or
promote apoptosis. NF-kB appears to be used as a genetic
switch whose biological effect is determined by the set of
genes it can access in a given cell type.
An interesting consequence of the recently uncovered anti-
apoptotic role of NF-kB is that it may be difficult pharmaco-
logically to block NF-kB-activating pathways without
increasing a cell’s susceptibility to cytotoxic stimuli. While
this may be desirable when treating tumors with cytotoxic
chemotherapeutics, it may not be advantageous when treat-
ing chronic inflammatory diseases with NF-kB inhibitors. A
number of drugs that treat rheumatoid arthritis were
recently recognized to be inhibitors of NF-kB, including
glucocorticoids, salicylates and gold compounds [15]. A char-
acteristic of glucocorticoids and salicylates is that they only
achieve a partial inhibition of NF-kB which, while still
allowing for a protection from apoptosis, may be sufficient to
significantly reduce the production of inflammatory cell-
adhesion molecules and cytokines. The future development
of anti-inflammatory drugs that target NF-kB, and improved
chemotherapeutic treatments, will certainly benefit from
the recent findings that prompted this commentary.
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